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Background: Enhanced production of endothelin-l (ET-
I), vasoconstrictive 21 amino acids produced by endo-
thelial cells during ischemia and after reperfusion of 
the liver, is known to cause sinusoidal constriction and 
microcirculatory disturbances, which lead to severe tis-
sue damage. Using a 2-hour hepatic vascular exclusion 
model in dogs, we tested our hypothesis that neutral-
ization of ET-l by monoclonal anti-ET-l and anti-ET-2 
antibody (AwETN40) abates vascular dysfunction and 
ameliorates ischemia/reperfusion injury of the liver. 
Study Design: Mter skeletonization, the liver was made 
totally ischemic by cross-clamping the portal vein, the 
hepatic artery. and the vena cava (above and below the 
liver). Veno-venous bypass was used to decompress 
splanchnic and inferior systemic congestion. AwETN40, 5 
mg/kg, was administered intravenously 10 minutes be-
fore ischemia (treatment group, n = 5). Nontreated 
animals were used as controls (control group, n = 10). 
Animal survival, hepatic tissue blood flow, liver func-
tion tests, total bile acid, high-energy phosphate. ET-I 
levels. and liver histopathology were studied. 
Results: Treatment with AwETN40 improved 2-week an-
imal survival from 30% to 100%. Hepatic tissue blood 
flow after reperfusion was significantly higher in the 
treatment group. The treatment significantly attenu-
ated liver enzyme release, total bile acid, and changes in 
adenine nudeotides. Immunoreactive ET-Ilevels in the 
hepatic venous blood of the control group showed a 
significant increase and remained high for up to 24 
hours after reperfusion. Histopathologic alterations 
were significantly lessened in the treatment group. 
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Conclusions: These results indicate that ET-l is involved 
in ischemia/reperfusion injury of the liver, which can 
be ameliorated by the monoclonal anti-ET-l and anti-
ET-2 antibody AwETN40. (j Am ColI Surg 1997;185: 
358-364. © 1997 by the American College of Sur-
geons) 
Endothelins (ETs), a group of vasoconstrictive 21 
amino acids identified by Yanagisawa and col-
leagues (1), are involved in the pathogenesis of 
various disorders of the liver. They play regulatory 
roles in the hepatic microcirculation and exert 
glycogenolytic actions in the liver (2). In particu-
lar, ET-l, synthesized by sinusoidal cells and cata-
bolized by hepatocytes (3), induces Ca2 + release 
and stimulation of glycogen phosphorylase in 
hepatocytes (4), constriction of Ito cells (5), and 
stimulation of platelet-activating factor in Kupffer 
cells (6), More important, production of ET-1 is 
enhanced during ischemia and after reperfusion 
in the liver and causes sinusoidal constriction, 
leading to severe microcirculatory disturbances 
and tissue damage (7), 
In this study. we examined the role of ET-1 in 
ischemia-induced liver damage in dogs by block-
ing its action with a novel anti-ET-l and anti-ET-2 
monoclonal antibody, AwETN40, 
Methods 
AKnirn{/i~I . ,\dul t female beag-Ie dogs weighing-
~-1O kg were used, This stud" was conducted with 
the approval of the Institutional Animal Care and 
Use Committee, and all animals were cared for 
according to 1'\ational Institutes of Health guide-
lines. After overnight !;lsting. the animals were 
anesthetized with thiopclltal sodium (25 mg/ kg) 
for inductioll, ;lnd ancsthesia was maintained with 
isotlurallt'. nitrous oxide, ;lnd oxygen bv positive 
pressure mechanical \'t'lltilalion. The right carotid 
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arterY and right jugular vein were cannulated 101 
monitoring arterial pressure and central \TIlOllS 
pressure and for obtaining blood samples. Electro-
cardiograph results and esophageal templDratllfq~ 
were monitored during the operatioll. Electrolvtl' 
solution (Plasmalvte. Travenol Laboratories. De'er-
field. IL) was infu~ed (20 mL . kg - I ·h - I) through-
out the operation to maintain adequate hydration 
and hemodynamic indices. Blood gases and elec-
trolvtes were measured frequently and corrected if 
necessary. 
Operative procedures. After entering the abdomen 
through a midline incision, we skeletonized the 
liver by dividing all of the suspensory hepatic lig-
aments. A venous catheter, Intracath 16GA (Bec-
ton Dickinson Vascular Access, Sandy, UT), was 
inserted into the suprahepatic inferior vena cava 
and positioned in the left hepatic vein for collect-
ing hepatic venous blood samples. The catheter 
was tunneled beneath the skin and exteriorized 
between the scapulae to allow serial blood sam-
pling after the operation. Total hepatic vascular 
exclusion was initiated by cross-clamping the por-
tal vein, hepatic artery, and infra- and supra-
hepatic inferior vena cava. Pump-driven vena-
venous bypass (Biomedics, Minetonka, MN) was 
used to decompress the splanchnic venous bed 
and infrahepatic inferior vena cava (8). The by-
pass circuit connected the left femoral vein and 
the splenic vein to the left jugular vein. The ani-
mals were given heparin (50 U/kg) 5 minutes 
before the initiation of ischemia. After 2 hours of 
ischemia, the liver was reperfused, the bypass sys-
tem was removed, and a splenectomy was per-
formed. Cefamandole nafate (1 g) was adminis-
tered intraoperatively and continued for 3 
postoperative days. The animals were allowed to 
eat and drink the morning after the operation and 
were followed for 2 weeks. 
Experimental groups. AwETN40, a monoclonal 
anti-ET-l and anti-ET-2 antibody, was supplied by 
Takeda Chemical Industries Ltd. (Osaka, Japan). 
AwETN40 dissolved in saline was administered in-
travenously, at a dose of 5 mg/kg, 10 minutes 
before the initiation of ischemia (treatmen t 
group, n = 5). Animals receiving saline alone were 
used as controls (control group, n = 10). 
Determinations. Two-week animal survival. liver 
function tests. total bile acid (TBA). hepatic tissue 
blood now (HTBF), tissue biochemistry. histopa-
thology, and ET levels were used to e\'aluate the 
effican of the treatment in this stud\,. Peripheral 
\'enous blood samples were collected seriallv for 
determination of liver enzymes, including aspar-
tate aminotransferase. alanine aminotransferase, 
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and lactate dehwlrogenase. In' a Techllicol1 RA:'>OO 
~llltoal1alyzer (Baver. Tarn"towl1, 1\1'). Serum TBA 
yyD~fp measured hv the enzvmatic [1uorometric 
lIIethod using the Sterongnost-alpha Flu Kit (Nve-
gaad. Oslo. Norway) (9). Serial measurements of 
IITBF were performed intraoperatively using a 
laser Doppler f10wmeter (Advance Laser Flow-
meter. ALF21; Advance Company Ltd., Tokyo,Ja-
pan). The probe was placed on three lobes of the 
liver until a stable flow value was obtained. To 
avoid a misreading in HTBF measurements re-
lated to respiratory motion, the ventilation was 
always stopped briefly. The mean of these three 
values was used as the representative value and was 
expressed as a percentage of the value of the 
preischemia level. 
Wedge liver biopsies collected before ischemia, 
at the end of ischemia, and 15 minutes and 60 
minutes after reperfusion were diced into small 
pieces and immediately transferred into liquid ni-
trogen for the determination of adenine nucleo-
tides. Concentrations of adenine nucleotides were 
measured using a Waters high-performance liquid 
chromatography system (Waters Chromatography 
Division/Millipore Corp., Milford, MA; Model 484 
absorbance module and Model 717 WISP system) 
at 254 nm (Waters 484, Tunable Absorbance De-
tector) (10). Energy charge was calculated using 
the equation [ATP + Y2 ADP]! [ATP + ADP + 
AMP], in which ATP = adenosine triphosphate, 
ADP = adenosine diphosphate, and AMP = aden-
osine monophosphate. The other tissues were 
fixed in buffered formalin and stained with hema-
toxylin and eosin. Histopathology was examined 
by a single pathologist without knowledge of the 
groups or the timing of tissue sampling. Histologic 
assessment was performed semiquantitatively 
based on the degree of sinusoidal congestion, 
sinusoidal derangement, ischemic hepatocyte in-
jury, and hepatocyte necrosis as follows: none = 0, 
mild = 1, moderate = 2, and severe = 3. The 
number of neutrophils infiltrated in the tissue was 
counted after Leder's staining (11) and expressed 
as that per 1,000 hepatocyte nuclei, 
Plasma concentration of imm unoreactive ET-l 
(irET-l) in the hepatic venous blood was mea-
sured by radioimmunoassav (12). The 4-mL blood 
samples, collected in a Vacutainar 6452 tube (Bec-
ton Dickinson Vacutainer Systems, Rutherford, 
NJ) with 7.5 mg of ethvlenediamine tetraacetic 
acid, were centrifuged at 2.800 x g and 4°C for 10 
minutes and were stored at - SO°C until the assay. 
Samples and standards (ET-l; Peninsula Labora-
tories, Belmont. CA.) were reconstituted in assav 
buffer and incubated for 24 hours with rabbit 
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FIG 1. Animal survival after the operation. *p < 0.05 ver-
sus control. Aw. AwETN40 (treatment group), 
anti-ET-1 serum (RIK-6901; Peninsula Laborato-
ries) at 4°C. The addition ofiodine125 ET-1 (Pen-
insula Laboratories) was followed by a second 24-
hour incubation, and bound and free radio ligand 
were separated using the second antibody 
method. Sound radioactivity data were evaluated 
after logit/log transformation, and the irET-1 data 
were presented after correction for recovery. The 
rabbit antiserum exhibited a cross-reactivity of 
17% with human big ET-1 and of 7% with ET-3, 
but no cross-reactivity with unrelated peptides (ie, 
atrial natriuretic peptide, brain natriuretic pep-
tide, vasopressin, and angiotensins I, II, and III). 
The standard curve was verY stable, with a mid-
point (50% inhibitory co'ncentration) of 14 
pg/tube. 
Slatistimi analvsis. Values were expressed as 
mean:!: standard error of the mean (SEM). Ani-
mal survival was compared using X'!. test. Intra-
group analysis was performed using Wilcoxon 
signed-rank test: intergroup analysis was per-
formed lIsing Mann-Whitney U test. A p value < 
0.05 was considered statisticallv signiticant. 
Results 
Sun/;lIai. .\11 of the animals treated with 
.\wETN..t-O survived for 1,-1- davs after the operation, 
hill 7 or 10 control dogs dicd of' livcr bil\ll'c. The 
survival rate ill the trcatlllelll group was sig'nifi-
cantl\' higher than that in the cOlllrol ~r{Flfp (p <.: 
11.(5) Eci~K I). 
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FIG 2. Changes in hepatic tissue blood flow (HTBF) dur-
ing ischemia and after reperfusion. Values are expressed as a 
percentage of the preischemic HTBF level. Bars express SEM, 
*p < 0.01 versus control. Aw, AwETN40. 
and fell considerably immediately after reperfu-
sion. Our operational procedure produced c.o.m-
plete liver ischemia, but there was false-posltlve 
tissue blood flow by Doppler flow measurement 
during ischemia, ranging from 8-11 ~ of the. pre-
ischemia levels (Fig. 2). The restoratton of tlssue 
blood flow after reperfusion was significantly bet-
ter in the treated animals than in the controls. 
Liver enz.yme levels. After reperfusion, levels of 
aspartate aminotransferase, alanine aminotrans-
ferase, and lactate dehydrogenase were signifi-
cantly lower in the AwETN40-treated animals than 
in control animals (Fig. 3; Table 1). 
Total bile acid. Table 1 details the changes in the 
TSA levels in the control and treatment groups. 
TBA levels in the treatment group reached a peak 
12500 
__ Control 
10000 
__ Aw 
::r 
:3 7500 -
-
.... 
~ 5000 
2500 
ori----------~~~~ __ 4---
pre lhr 6hr 24hr 3davs 7davs 14davs 
Time after reperfusion 
F((; :\, (:klllg(·' ill ;I'pal'lal(' alllillOll'allsti.-rase (AST) ailer 
I'l'p('rlnsioll, Hal'S e'pn'ss SE\I; tllIl\' olle-sided SEM is prl'-
'('llIed, "'p <- 11,11:-, \',·"us «(11111'(11: "*p "- (Ull "("I'SUS ('olltrol. 
,\w .. \\\'ET:-':IO, 
Urakami et al ISCHEMIC LIVER INJURY 361 
Table 1. .\lanine Aminotransferase. Lactate Dehydrogenase. and Total Bile Acid After Reperfusion 
Measurement Croup Preischemia 
ALT (L'/U Control 
Aw 
LDH (DIU Control 
Aw 
TBA (Ilmol/L) Control 
Aw 
*p <; 0.05 versus control value. 
tp < 0.01 verslis control vallie. 
~tK!KO :: ~KO 
32.0 = 4.5 
80.6 = 15.7 
53.0 = 15.7 
0.3:!: 0.3 
2.4 :!: 1.0 
30 min tiO min 
-Ul46 = 1.!iiS 4.% 1 :t T~FU 
~KOOO :: 699 :!,373 :!: 897 
:~IOM9 = I.D7G :U8,) = ·t74 
2.378 = 624 2.004 = 732 
36.3:!: 7.9 48.5:!: 11.7 
67.2 :!: 5.0* :;9.4 = 14.9 
:) h tih 12 h 24 h 
6.575 = 1.007 9.332 = 1.128 13.563 = 1.379 12,680 = U51 
2.842 = 807* 3,344 = 9H t 3.505 = 925 t 3,439 = 1.612t 
:'.,128 = 479 2.906 = ')59 3,045 = 634 1,440=216 
1.533 = 423 1.148 = 161 * 561 = 125* 261 :!: 25.5 t 
100:!:11.0 133.8 :!: 11.8 124.3:!: 13.1 175.4 = 39.0 
'l7.4 :!: 31.1 102.4 :!: 24_6 44.6:!: 14_9t 30.4 :!: 12.3* 
,\LT, alanine allllllotransferase: Aw. AwJ::TN40: LDH. lactate dehydrogenase: TBA. total bile acid. 
value at 6 hours after reperfusion and declined 
thereafter; levels in the control group continued 
to increase until 24 hours after reperfusion. 
Endothelin levels. Changes in irET-1 levels in the 
hepatic venous blood in the control group are 
shown in Figure 4. Reperfusion of the liver after 2 
hours of ischemia induced a significant rise in 
irET levels, by 4 times from 5 minutes to 60 min-
utes, 7 times at 3 hours, and> 18 times thereafter. 
Measurement of irET-1 in the treatment group 
failed because of the competitive nature of 
AwETN40 against the radioimmunoassay method 
used in this study. 
Adenine nucleotides. Treatment 'with AwETN40 
slowed the degradation of adenine nucleotides 
during ischemia and enhanced energy resynthesis 
after reperfusion (Table 2). Adenosine triphos-
phate levels and total adenine nucleotide levels in 
the treatment group at 15 minutes and 60 minutes 
after reperfusion were significantly higher than 
those in the control group. Energy charge showed 
no significant difference between the groups. 
Histology. Although no significant histologic dif-
ferences were found at the end of 2-hour ischemia 
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and at 15 minutes after reperfusion, the treatment 
group showed significantly less structural damage 
and neutrophil infiltration in the liver than the 
control group. In particular, hepatocyte necrosis 
was not seen in any of the treatment-group ani-
mals (Table 3). 
Discussion 
In this study, we demonstrated that the neutraliza-
tion of ET-1 by AwETN40 lessened microcircula-
tory disturbance, attenuated ischemia/reperfusion 
i~uryI and improved animal survival. In addition, 
pretreatment with AwETN40 slowed enzyme leak-
age, inhibited adenine nucleotide degradation in 
ischemic tissues, enhanced ATP resynthesis, and 
improved histopathologic findings. 
Endothelins are a group of related 21-amino 
acid peptides (ET-1, ET-2, and ET-3) , which bind 
to three differen t types of ET receptors (ETA' ET B' 
and ETd (13). In addition. two subtypes of ETB 
receptors have been identified. ET HI and bqly~ 
(14). ET\, has a high affinity for ET-1 and ET-2. 
but a low at1inity for ET-3. ETn has an equallv 
potent affinity for ET-l, -2, and -3 (15). The ET", 
receptor generally has been accepted as the pre-
dominant receptor subtype associated with vaso-
constriction. The ETBI receptor is located in the 
endothelial cell and mediates vasodilation 
through the release of nitric oxide and prostacy-
din. The bqB~ receptor is located on the vascular 
smooth muscle cells and mediates vasoconstric-
tion directlv (l()). In the liver. the number of these 
ET receptors per cdl is :~EF-EFl-fold higher on [to 
cells than on sinusoidal endothelial cells or hepa-
tocvtes (17). The abundance of ET receptors Oil 
Ito cells suggests that these cells are a major target 
for ET in the liver. Ito cells extend their numerous 
long cvtoplasmic processes to surround the sinu-
soidal wall and are involved in reducing the he-
patic sinusoidal minocirculation bv contraction 
( 1 R), .\mong variolls ETs. it has been shown that 
ET-! is a llIajor ET produced bv ischemia ;1I1d 
I 
, I 
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Table 2. Tissue Concentrations of Adenine Nucleotides During Ischemia and After Reperfusion 
ATP ADP AMP qAt~ EC 
Time Group (nmol/g tissue) (nmol/g tissue) (nmol/g tissue) (nmol/g tissue) (nmol/g tissue) 
Preischemia Control ~KSSSKO ::':: ~UPKR 894.0 ::':: 111.2 ~1PKS ::':: ~SK4 3.773.7 ::':: ~USKT 0.8229::':: 0.017 
2 h alter ischemia Control 236.9::':: 40.4 335.0 ::':: 29.1 1.147.1::':: 95.9 1.718.9 ::':: 1POK~ 0.2337 ::: 0.024 
Aw 357.0::':: 61.5 422.6::':: 94.2 1.537.7::':: 98.2* 2.317.3::':: 165.1* 0.2401 ::':: 0.031 
15 min after reperfusion Control 846.8 ::':: 152.2 409.9::':: 65.6 160.0::':: 15.9 1.416.8 ::':: 209.3 0.7229 ::':: 0.036 
Aw 1.905.3 ::': 233.9' 623.7 ::':: 82.3* 252.7::: 21.1 * 2.781.6::':: 275.2' 0.7943::':: 0.015 
60 min after reperfusion Control 1,227.2::': 123.7 329.4 ::': 33.4 112.2::': 13,1 1.668,8::': 143.2 0.8324::':: 0,014 
Aw 1,994,2 ::':: 171.8* 517,9 ::':: 73.0* 268.4::':: 48.5 2.780.6::':: 137.1' 0.8093 ::: 0.030 
*p < 0.05 versus control value. 
'p < 0.01 versus control value. 
ATP, adenosine triphosphate; ADP. adenosine diphosphate; AMP. adenosine monophosphate; TA."I. total adenine nucleotides; EC, energy charge; Aw. AwETN40. 
reperfusion, and that both ETA and ET B receptors 
are located on the cell membrane ofIto cells (15). 
Endothelin can be divided into two structural 
portions: (1) the N-terminal 15 amino acids, hav-
ing a rigid structure with two disulfide bonds; and 
(2) the C-terminal heptapeptide, consisting of rel-
atively hydrophobic amino acids. AwETN40 is a 
monoclonal antibody for ET-l and ET-2 that rec-
ognizes only the N terminal and not the C termi-
nal. Although AwETN40 was first developed for 
the sandwich enzyme immunoassay for ET-l (19), 
it has also proved effective in preventing myocar-
dial infarction (20), acute renal failure (21), liver 
ischemia (22, 23), and endotoxin-induced liver 
injury (24) by its neutralizing activity against ET-l 
and ET-2. 
The dosage of AwETN40 used in this experi-
ment was based on previous reports. Watanabe 
and associates (20) showed that the effect of ex-
ogenous ET-l administration (0.75 mg/kg) on 
blood pressure was neutralized by pretreating an-
imals with 1.5-4.5 mg/kg of AwETN40. They also 
found that the effect of 22.5 mg/kg AwETN40 
lasted for > 24 hours. Using a I-hour partial 
(70%) liver ischemia model in dogs, Kawamura 
and colleagues (23) reported that pretreatment 
Table :~K Histologic Findings 
with 2 mg/kg of AwETN40 was effective in atten-
uating ischemia/ reperfusion injury. Thus, we con-
sidered that the dosage of AwETN40 in this study, 
5 mg/kg, would be sufficient for neutralization of 
ET-l in ischemia/reperfusion injury in the 2-hour 
total hepatic vascular exclusion model in dogs. 
In this study, the concentration of irET-l in 
hepatic venous blood increased immediately after 
reperfusion and remained markedly elevated for 
up to 24 hours above 15.9 :t 7.1 pg/mL. Naka-
mura and associates (22) reported that irET-l in-
creased to 12 pg/mL at 3 hours after reperfusion 
using a 60-minute total liver ischemia model in 
rats. Kawamura and colleagues (23) reported that 
irET-I increased to 6 pg/mL at 3 hours after 
reperfusion using the I-hour partial liver ischemia 
model in dogs. The different concentrations of 
irET-I between these studies may depend on the 
difference in species, the duration of ischemic 
time, the timing of the measurement, and the 
amount of ischemic liver damage. Levels of ET-l 
in the circulation after ischemia and reperfusion 
are influenced by the balance between production 
and its clearance by the il~ured liver. It has been 
demonstrated that hypoxia induces ET-I gene ex-
pression and secretion in endothelial cells (25), 
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which is regulated by the degree of ischemia and 
the duration of reperfusion. In addition, inter-
leukin-l, tumor necrosis factor, and transforming 
growth factor-l3, all of which are up-regulated by 
ischemia and reperfusion, stimulate ET-l produc-
tion and release from sinusoidal endothelial cells 
(26). Clearance of ET is markedly reduced in 
injured livers as compared with nonnalliyers (23). 
Exogenous ET-I has been shown to cause a 
pronounced elevation of intrahepatic vascular re-
sistance, resulting in a profound decrease in he-
patic blood flow and a refractory increase in portal 
pressure (2). In this study, although there was no 
difference in mean arterial pressure between the 
groups, preischemic administration of AwETN40 
markedly improved HTBF after reperfusion. How-
ever, HTBF did not reach the preischemic level 
during the I-hour observation period, suggesting 
that the effect of this agent may not be sufficient 
or that there are other factors involved. First, 
AwETN40 barely moves from the bloodstream into 
the interstitial space because of its large molecular 
weight. It may bind easily to ET in the circulation, 
but it is more difficult to trap ET in the interstitial 
space, even if a sufficient dose of the agent is given 
intravenously. Second, ET-I exerts its action by an 
autocrine or paracrine mechanism. Ito cells have a 
very low level of ET-I mRNA in the normal liver, 
but it increases significantly once the liver receives 
ischemic insults (27). In addition, when ET-I is 
produced by endothelial cells, 80% of the ET-I is 
released into the interstitial space rather than into 
the circulation (28). Finally, insufficient restora-
tion of HTBF in this stud~ may relate to other 
impaired endothelial cell functions, such as re-
duced svnthesis of nitric oxide and prostaglandins 
(29). 
The determination of serum TBA is a sensitive 
and specific index for hepatobiliary disorders that 
depends on the synthesis and excretory functions 
of hepatocvtes and the hepatic blood flow (30). As 
shown in the present study, TBA increased imme-
diately after reperfusion and remained high ill the 
control group for up to 24 hours; TilA levels in the 
treatment group began to decrease after 6 hours. 
indicating better hepatocyte function and greater 
hepatic blood flow. 
.-\denosine triphosphate is the most hasic factor 
in mailllaining functional and structural ilHegritv 
of hepatoC\'tes t31 ). Reduction of ATP levels leads 
directl\' to the disturbance of cellular i11legritY and 
exacerbation of cellular dysfunctioll. Endothelin-l 
!OWCl'S A TP levels by increased consllmption (2) or 
inhibits ATP synthesis bv slIppressing the oxvgen 
suppl\" lhrollgh ';lSocollslrinioll (:t!L PrelreLlt-
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ment with AwETN40 abated these adverse effects 
of ET-I in this study. 
The number of polymorphonuclear neutrophils 
(PMNs) infiltrated in postischemic liver tissue was 
significantly reduced by AwETN40 treatment. 
Polymorphonuclear neutrophils playa crucial role 
in the progression of ischemia/reperfusion injurv 
(33). During interactions ofPMNs and ET-I, ET-I 
has been shown to stimulate migration and aggre-
gation of PMNs (34) and to enhance superoxide 
anion production by the chemotactic peptide N-
formyl-methionyl-Ieucyl-phenylalanine (35) . On 
the other hand, PMNs increase the induction of 
ET-I mRNA expression in endothelial cells (36) 
and convert big ET to ET-I (37). Furthermore, 
ET-I stimulates the expression of adhesive mole-
cules, CDll/CD18 integrin, on the neutrophil 
surface (38). The expression of intercellular adhe-
sion molecule-l and vascular cell adhesion 
molecule-Ion cerebromicrovascular endothelial 
cell lines is also up-regulated by ET-I (39). These 
observations suggest that ET-I exerts influence on 
PMNs by facilitating their adhesion to endothelial 
cells and infiltration into the tissue. Consequently, 
the neutralization of ET-I by AwETN40 appears, 
in part, to suppress PMNs' adhesion to endothelial 
cells, lessen PMNs' activation, and attenuate liver 
injury. 
We postulated the following scenario on the 
basis of our findings. Two hours of ischemia causes 
extensive damage to sinusoidal endothelial cells in 
the liver. The damage triggers the production and 
release of endogenous ET-I that induces the con-
striction of Ito cells. leading to sinusoidal constric-
tion and microcirculatory disturbances. The re-
duction in blood f10w augments postischemic 
tissue injury. In addition, ET-I enhances the vari-
ous adverse actions of PMNs. The neutralization of 
ET-I by the monoclonal antibody AwETN40 is 
considered to contribute to the attenuation of 
liver damage bv inhibiting sinusoidal constriction 
and PMN action. which are involved in the patho-
genesis of ischemia/ reperfusion injury of the liver. 
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